General
Preferred name
ALENDRONIC ACID
Synonyms
ALENDRONATE SODIUM TRIHYDRATE ()
G-704650 Adronat ()
alendronate ()
Alendronate sodium ()
Fosomax / Alendros ()
alendronate sodium iv, Teijin ()
Alendronate (sodium hydrate) ()
Alendronic acid (monosodium salt) ()
MK 217 ()
G-704650, MK-217 ()
Acido alendronico ()
Acide alendronique ()
Binosto ()
Fosamax ()
Sodium alendronate ()
MK-217 ()
Alendronic acid monosodium salt trihydrate ()
Alendronate (as sodium) ()
NSC-722597 ()
NSC-758931 ()
Alendronate sodium component of fosamax plus d ()
Adrovance ()
G-704,650 ()
Vantavo ()
Fosavance ()
G-704650 ()
Alendronate sodium hydrate ()
Sodium alendronate trihydrate ()
P&D ID
PD009879
CAS
121268-17-5
66376-36-1
129318-43-0
Tags
available
drug
Approved by
FDA
First approval
1995
Drug indication
Osteoporosis
Paget's disease
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
HALF-LIFE Due to alendronic acid being incorporated into the skeleton, the terminal half life is estimated to be over 10 years[FDA Label].
PHARMACODYNAMICS Alendronic acid tablets have a very low oral bioavialability[FDA Label][A176750]. After administration it distributes into soft tissue and bone or is excreted in the urine[FDA Label]. Alendronic acid does not undergo metabolism[FDA Label].
MOA Alendronic acid binds to bone hydroxyapatite[FDA Label]. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis[A959]. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis[A959]. Inhibition of osteoclasts results in decreased bone resorption which is shown through decreased urinary calcium, deoxypyridinoline and cross-linked N-telopeptidases of type I collagen[FDA Label].
INDICATION Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
ROE Administration of radiolabeled alendronic acid results in 50% recovery in urine within 72 hours[FDA Label][A176771]. No alendronic acid is recovered in the feces[FDA Label][A176750,A176768]. Men excrete less alendronic acid than women, though race and advanced age do not affect elimination[FDA Label].
METABOLISM Urinary excretion is the sole method of elimination of alendronic acid and no metabolites are detected upon urine collection[A176750].
ABSORPTION Mean oral bioavailability of alendronic acid in women is 0.64% and in men is 0.59%[FDA Label][A176750]. Bioavailability of alendronic acid decreases by up to 40% if it is taken within an hour of a meal[FDA Label].
DESCRIPTION Alendronate is a bisphosphonate drug. (GtoPdb)
TOXICITY In clinical studies, ≥3% of patients experience abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, and nausea[FDA Label].; ; No information for treatment of overdose is available, however patients should be given milk or antacids to bind alendronic acid and vomiting should not be induced[FDA Label]. Patients may experience hypocalcemia, hypophosphatemia, and upper gastrointestinal events.[FDA Label].; ; There are currently no studies for safety and efficacy in pregnancy, though studies in pregnant rats show fetal and maternal complications at 4 times the clinical dose and pregnant rabbits do not show complications at as high as 10 times the clincal dose[FDA Label].; ; Excretion in breast milk, and therefore safety in lactation, is unknown[FDA Label].; ; Alendronic acid has been studied for use in pediatric patients[FDA Label]. The oral bioavailability is similar to that in adult patients, but an increase in the portion of patients experiencing vomiting[FDA Label].; ; There is no significant difference in efficacy or safety of alendronic acid in geriatric populations, though there is potential for even greater sensitivity in patients at a further advanced age than those in the study[FDA Label].; ; Alendronic acid is not recommended for patients with creatinine clearance <35mL/min, but no dosage adjustment is necessary in hepatic impairment[FDA Label].
PRICE 29
DESCRIPTION Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis[1].
DESCRIPTION Alendronate, a nitrogen-containing bisphosphonate, is a potent inhibitor of bone resorption used for the treatment and prevention of osteoporosis. (BOC Sciences Bioactive Compounds)
DESCRIPTION Alendronate sodium hydrate (MK 217) is a nitrogen-containing bisphosphonate, which is an effective inhibitor of bone resorption. It is utilized for the treatment and prevention of osteoporosis. (TargetMol Bioactive Compound Library)
DESCRIPTION Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. Alendronic acid binds to bone hydroxyapatite. (Enamine Bioactive Compounds)
DESCRIPTION Alendronic Acid (alendronate) is a nonhormonal medication used for osteoporosis, osteogenesis imperfecta, and several other bone diseases. (TargetMol Bioactive Compound Library)
Cell lines
4
Organisms
6
Compound Sets
32
BOC Sciences Bioactive Compounds
alendronate-sodium-hydrate-cas-121268-17-5-item-84-298964
Cayman Chemical Bioactives
13642
ChEMBL Approved Drugs
CHEMBL870
CHEMBL675
ChEMBL Drugs
CHEMBL870
CHEMBL675
Concise Guide to Pharmacology 2017/18
3141
Concise Guide to Pharmacology 2019/20
3141
Concise Guide to Pharmacology 2021/22
3141
Concise Guide to Pharmacology 2023/24
3141
Drug Repurposing Hub
DrugBank
DB00630
DrugBank Approved Drugs
DB00630
DrugCentral
112
DrugCentral Approved Drugs
112
DrugMAP
DMY2KX9
DrugMAP Approved Drugs
DMY2KX9
DrugMatrix
Enamine Bioactive Compounds
EBC-04173
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS102401
Guide to Pharmacology
3141
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL870
MedChem Express Bioactive Compound Library
HY-B0631
HY-108685
HY-11101
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
X1J18R4W8P
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Alendronate-Sodium(Fosamax)
TargetMol Bioactive Compound Library
T6373
T7469
The Spectrum Collection
External IDs
109
Properties
(calculated by RDKit )
Molecular Weight
249.02
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
6
Rotatable Bonds
5
Ring Count
0
Aromatic Ring Count
0
cLogP
-1.27
TPSA
161.31
Fraction CSP3
1.0
Chiral centers
0.0
Largest ring
0.0
QED
0.33
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Farnesyl diphosphate synthase
ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS
Bacterial
MOA
Transferase inhibitor
Protein Tyrosine Phosphatase (PTP) Inhibitors
Farnesyl Pyrophosphate Synthase Inhibitors
"Protein Tyrosine Phosphatase (PTP) Inhibitors
Farnesyl Pyrophosphate Synthase Inhibitors"
bone resorption inhibitor
Member status
member
Indication
osteoporosis
Pathway
Metabolism
Anti-infection
Therapeutic Indication
Calcium Metabolism
Therapeutic Class
Hormone Therapy
Bone Density Conservation Agents
Source data